Eli Lilly and Company $LLY Shares Purchased by Ritholtz Wealth Management

Key Points

• Ritholtz Wealth Management increased its stake in Eli Lilly by 5.1%, acquiring an additional 1,065 shares, leading to a total of 22,139 shares valued at $17.26 million.
• Eli Lilly reported $6.31 EPS for the latest quarter, surpassing estimates and reflecting a 37.6% year-over-year revenue growth to $15.56 billion.
• Insiders, including the CEO and a director, recently purchased shares at an average price around $644, indicating continued confidence in the company's performance.

Ritholtz Wealth Management grew its position in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 5.1% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 22,139 shares of the company's stock after acquiring an additional 1,065 shares during the quarter. Ritholtz Wealth Management's holdings in Eli Lilly and Company were worth $17,258,000 at the end of the most recent quarter.

Other large investors also recently modified their holdings of the company. WestEnd Advisors LLC grew its stake in Eli Lilly and Company by 210.0% during the first quarter. WestEnd Advisors LLC now owns 31 shares of the company's stock worth $26,000 after buying an additional 21 shares during the period. Wealth Preservation Advisors LLC purchased a new position in shares of Eli Lilly and Company in the 1st quarter valued at $27,000. Citizens National Bank Trust Department lifted its holdings in shares of Eli Lilly and Company by 180.0% during the 1st quarter. Citizens National Bank Trust Department now owns 42 shares of the company's stock valued at $35,000 after acquiring an additional 27 shares in the last quarter. Financial Gravity Asset Management Inc. purchased a new stake in Eli Lilly and Company during the 1st quarter worth $40,000. Finally, TD Capital Management LLC increased its holdings in Eli Lilly and Company by 129.2% in the 1st quarter. TD Capital Management LLC now owns 55 shares of the company's stock valued at $46,000 after purchasing an additional 31 shares in the last quarter. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Eli Lilly and Company Price Performance

LLY stock opened at $812.65 on Wednesday. The stock's 50 day moving average is $744.36 and its two-hundred day moving average is $765.86. Eli Lilly and Company has a 52-week low of $623.78 and a 52-week high of $935.63. The company has a market capitalization of $769.14 billion, a PE ratio of 53.11, a P/E/G ratio of 1.17 and a beta of 0.47. The company has a quick ratio of 1.00, a current ratio of 1.28 and a debt-to-equity ratio of 1.86.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its earnings results on Thursday, August 7th. The company reported $6.31 EPS for the quarter, beating the consensus estimate of $5.59 by $0.72. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The company had revenue of $15.56 billion during the quarter, compared to analysts' expectations of $14.40 billion. During the same period in the prior year, the business posted $3.92 EPS. The business's revenue was up 37.6% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. Analysts predict that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Insider Activity at Eli Lilly and Company

In related news, Director J Erik Fyrwald acquired 1,565 shares of the firm's stock in a transaction on Tuesday, August 12th. The stock was bought at an average cost of $642.33 per share, with a total value of $1,005,246.45. Following the acquisition, the director directly owned 74,578 shares in the company, valued at approximately $47,903,686.74. The trade was a 2.14% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO David A. Ricks bought 1,632 shares of the business's stock in a transaction dated Tuesday, August 12th. The stock was bought at an average price of $644.77 per share, for a total transaction of $1,052,264.64. Following the purchase, the chief executive officer owned 546,601 shares in the company, valued at approximately $352,431,926.77. This represents a 0.30% increase in their position. The disclosure for this purchase can be found here. Insiders acquired 4,514 shares of company stock worth $2,894,841 over the last 90 days. Company insiders own 0.14% of the company's stock.

Analysts Set New Price Targets

A number of brokerages have commented on LLY. The Goldman Sachs Group boosted their price objective on Eli Lilly and Company from $876.00 to $879.00 and gave the stock a "buy" rating in a research note on Friday, October 10th. Morgan Stanley reduced their price target on Eli Lilly and Company from $1,028.00 to $1,023.00 and set an "overweight" rating on the stock in a research report on Friday, October 3rd. Cantor Fitzgerald set a $925.00 price objective on shares of Eli Lilly and Company and gave the company an "overweight" rating in a research report on Thursday, October 9th. JPMorgan Chase & Co. dropped their price objective on shares of Eli Lilly and Company from $1,100.00 to $1,050.00 and set an "overweight" rating on the stock in a research note on Tuesday, September 16th. Finally, Daiwa America downgraded shares of Eli Lilly and Company from a "strong-buy" rating to a "hold" rating in a research note on Sunday, August 17th. One investment analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating and nine have issued a Hold rating to the company's stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $948.06.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.